Skip to main content
An official website of the United States government
Headshot of Dr. Sherry Yang

Sherry Yang, M.D., Ph.D.

Medical Officer
Program Director
240-760-7147
|

Dr. Sherry Yang joined the Cancer Diagnosis Program as Medical Officer and Program Director in 2019. She oversees a research portfolio in the Program and has involved in special program projects such as biomarker review in Precision Medicine trials. Dr. Yang reviews and advises on procedures for the evaluation of prognostic and predictive markers for targeted therapies, immunotherapy and chemotherapy. She serves as a biomarker reviewer for CTEP-sponsored clinical trials and a member of the NCI ComboMATCH Molecular Biomarker and Specimen Management Committee. Dr. Yang initiated and implemented the treatment-associated and outcome-type weighted prognostic biomarker project at the Program, and progress has been made through large breast cancer cohort and phase III TAILORx trial studies. Through the role as the Chief of National Clinical Target Validation Laboratory from 2006 to 2019, her laboratory developed and validated pharmacodynamic, response or toxicity biomarkers as well as prognostic and predictive biomarkers to targeted therapy and conventional therapy. Dr. Yang joined the National Cancer Institute in 2001 from the Johns Hopkins Oncology Center, Baltimore, Maryland. Her 100 plus publications have over 7000 citations and she is a recipient of several biomarker-related awards and innovations. Focused on biomarker-driven cancer treatment, Dr. Yang has been an editor of Handbook of Therapeutic Biomarkers in Cancer since 2013.

Selected Publications

Additional Links to Scientific Publications

  • Updated:
Email